Media headlines about Novartis AG (NYSE:NVS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novartis AG earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the company an impact score of 91 out of 100, indicating that recent press coverage is extremely likely to have an impact on the stock’s share price in the near term.

These are some of the news articles that may have impacted Accern Sentiment Analysis’s scoring:

Shares of Novartis AG (NVS) traded down 0.47% during mid-day trading on Thursday, reaching $84.87. 962,708 shares of the company traded hands. The firm has a 50-day moving average price of $83.64 and a 200 day moving average price of $78.07. Novartis AG has a 52 week low of $66.93 and a 52 week high of $86.90. The firm has a market capitalization of $222.09 billion, a price-to-earnings ratio of 30.10 and a beta of 0.73.

Novartis AG (NYSE:NVS) last issued its quarterly earnings results on Tuesday, July 18th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.16 by $0.06. The firm had revenue of $12.24 billion for the quarter, compared to analyst estimates of $12.20 billion. Novartis AG had a return on equity of 15.51% and a net margin of 13.52%. The firm’s quarterly revenue was down 1.8% on a year-over-year basis. During the same period last year, the company earned $1.23 EPS. On average, analysts anticipate that Novartis AG will post $4.78 earnings per share for the current year.

NVS has been the topic of a number of analyst reports. Zacks Investment Research raised shares of Novartis AG from a “strong sell” rating to a “hold” rating in a research note on Monday, May 1st. Credit Suisse Group lowered shares of Novartis AG from a “neutral” rating to an “underperform” rating and set a $82.25 target price on the stock. in a research note on Wednesday, July 5th. Morgan Stanley reaffirmed a “sell” rating on shares of Novartis AG in a research note on Tuesday, June 6th. Leerink Swann reissued a “market perform” rating and set a $83.00 price objective on shares of Novartis AG in a research note on Thursday, June 22nd. Finally, J P Morgan Chase & Co reissued a “neutral” rating on shares of Novartis AG in a research note on Tuesday, April 18th. Four research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $81.71.

TRADEMARK VIOLATION NOTICE: “Somewhat Positive Press Coverage Extremely Likely to Impact Novartis AG (NVS) Share Price” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at

In other Novartis AG news, major shareholder Bioventures Ltd Novartis acquired 266,667 shares of the company’s stock in a transaction on Wednesday, July 5th. The shares were bought at an average cost of $15.00 per share, for a total transaction of $4,000,005.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.01% of the company’s stock.

Novartis AG Company Profile

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Insider Buying and Selling by Quarter for Novartis AG (NYSE:NVS)

Receive News & Stock Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related stocks with our FREE daily email newsletter.